Strontium ranelate 'could reduce fracture risk in women with osteoporosis'

The drug strontium ranelate can reduce the risk of fracture in post menopausal women with osteoporosis, a new study has shown.

The researchers from St Thomas' Hospital in London published their findings in the journal Arthritis and Rheumatism.

During the study, 5,091 women from 75 centres across Australia and Europe were monitored after being prescribed strontium ranelate or a placebo.

After five years, it was found that those given strontium ranelate (brand name Protelos) enjoyed a 43 per cent reduction in the risk of hip fractures; a 24 per cent drop in vertebral fractures; and a 15 per cent reduction in non-vertebral fractures.

In addition, the study indicated that the drug was well tolerated, with no adverse events reported.

Professor Tim Spector commented: "Osteoporosis treatment is long-term and yet there are few long-term randomised trials.

"It is therefore encouraging to see data demonstrating clear fracture prevention over five years. These results will improve our confidence further in our ability to improve long-term quality of life in our patients."

A spokeswoman for the Arthritis Research Campaign said that there were now a number of drugs effective at reducing bone loss in osteoporosis, but added that it was important that the condition was diagnosed more efficiently in order so that treatment could start.

Recent related stories:

Hyaluronan treatment shows 'good results in clinical trial'
08 October 2008
New osteoporosis drug 'shows good results' in Phase III trial
01 October 2008
New osteoporosis drug approved in Europe
01 October 2008
Adalimumab 'reduces bone loss in the hand'
23 September 2008
US regulators delay approval of new rheumatoid arthritis drug
19 September 2008
Osteoporosis drug 'shows promise' in two-year trial
18 September 2008
New juvenile arthritis drug shows good results in Phase I and II trial
18 September 2008

Want to know more?